Medtronic FY Conference Summary Company Overview - **Company**: Medtronic (NYSE: MDT) - **Date of Conference**: March 10, 2026 - **Key Speaker**: Thierry Piéton, CFO and EVP Key Points Industry Exposure and Impact - **Middle East Revenue Exposure**: Medtronic's revenue from the Middle East is approximately 2%-3% of total revenue, primarily from healthcare necessary products, indicating limited impact from regional conflicts [14][15] - **Oil Price Sensitivity**: Less than 1% of Medtronic's cost base is derived from petroleum derivatives, with existing contracts mitigating potential negative impacts from rising oil prices [16] MiniMed Business Separation - **Strategic Separation**: Medtronic is committed to separating the MiniMed business by the end of 2026, believing both entities will perform better independently [17] - **IPO Details**: An IPO for 10% of MiniMed was completed, with plans for a further split offering Medtronic shareholders the option to convert shares into MiniMed shares at a discount [41][42] - **Financial Implications**: The separation is expected to enhance EPS for Medtronic shareholders and allow for focused capital allocation [43] Financial Performance and Projections - **Growth Rates**: Medtronic anticipates organic growth in fiscal year 2027 to exceed that of fiscal year 2026, with a current growth trajectory of 5.5% to 6% [60] - **Gross Margin Improvement**: Expected improvements in gross margin due to operational enhancements and the separation of MiniMed [60] - **R&D Investment**: Continued increase in R&D spending as a percentage of sales, with a focus on high-growth areas [61] Cardiac Ablation Systems (CAS) Growth - **Market Position**: Medtronic is experiencing rapid growth in the CAS market, with a significant market share increase of 4 points in the third quarter [80] - **Product Differentiation**: The Sphere-9 catheter offers dual energy capabilities, enhancing procedural efficiency and patient outcomes [78] - **Supply Chain and Training**: Addressing supply chain bottlenecks and training for mappers to support growth in CAS procedures [82] Future Opportunities - **Ardian and Hugo Programs**: - **Ardian**: Expected to impact growth in fiscal year 2027, with a significant patient pool and high-margin potential [99] - **Hugo**: Recently received FDA approval, with plans to expand into various surgical indications, aiming for comprehensive market coverage [102][103] Challenges and Considerations - **Hiring and Training**: The need for experienced mappers poses a challenge, but Medtronic is actively hiring and training to meet demand [91][92] - **Market Competition**: The entry of competitors in the Hugo market necessitates a focus on customer satisfaction and optimal system installations [100][102] Conclusion - Medtronic is strategically positioning itself for growth through the separation of MiniMed, continued investment in R&D, and expansion in high-potential markets like CAS, Ardian, and Hugo. The company is optimistic about its financial outlook and operational improvements, despite facing challenges in hiring and market competition.

Group 1 - The company is experiencing a potential inflection point in growth rate, with expectations for acceleration in the second half of the year [1][2] - The new Executive VP & CFO believes that his automotive background can contribute incremental value to the company's performance [2] - Specific growth opportunities have been identified in areas such as cardiac ablation and other business segments [1]

Medtronic 2025 Conference Summary Company Overview - **Company**: Medtronic (NYSE: MDT) - **Date**: September 24, 2025 Key Industry Insights - **Growth Opportunities**: Medtronic is positioned for an inflection in growth, particularly in areas such as Cardiac Ablation, Ardian, and HUGO [3][4] - **Market Leadership Ambition**: The company aims to become the number one player in the electrophysiology (EP) market, leveraging strong product demand and upcoming innovations [63] Core Financial Insights - **EPS Growth Commitment**: Medtronic is targeting high single-digit EPS growth for the upcoming year, with a clear path to achieve this based on internal assessments [6][7] - **Gross Margin Recovery**: The company aims to recover gross margins to pre-COVID levels, currently about 380 basis points lower than before the pandemic [12][8] - **Operational Improvements**: Significant improvements in pricing and cost management are expected to contribute to gross margin recovery, with a target of 1% to 1.5% annual net cost reductions [14][15] Strategic Focus Areas - **Innovation Reinvestment**: Medtronic plans to reinvest a portion of the benefits from growth into innovation through both organic R&D and M&A activities [4][10] - **M&A Strategy**: The company is looking to pursue tuck-in acquisitions in the range of €1 billion to €4 billion, focusing on companies just before or after commercialization [51][52] - **Free Cash Flow Generation**: Medtronic generates over €5 billion in free cash flow and aims to improve this through better operating margins and working capital management [59][61] Operational Enhancements - **Supply Chain Optimization**: The company is working on reducing the number of suppliers and SKU reduction to enhance operational efficiency [33][34] - **Digital Surgery and HUGO**: The HUGO platform is expected to create a comprehensive ecosystem for surgical procedures, enhancing margins and competitiveness [68][69] Market Dynamics - **Cardiac Ablation and RDN**: The company sees significant potential in the RDN market, with a large patient base and expected rapid commercialization [72][73] - **Diabetes Business Divestiture**: Medtronic is in the process of divesting its diabetes business, which is expected to alleviate margin pressures [15][16] Governance and Shareholder Engagement - **Board Enhancements**: Following engagement with Elliott Management, Medtronic has added medtech expertise to its board and established dedicated committees for growth and operations [40][41] - **Shareholder Value Focus**: The company is committed to improving shareholder value through disciplined execution and strategic investments [49][50] Conclusion - Medtronic is strategically positioned for growth with a focus on innovation, operational efficiency, and shareholder value enhancement. The company is committed to recovering gross margins, achieving high EPS growth, and leveraging M&A opportunities to drive future success.

Financial Data and Key Metrics Changes - The company is focused on improving R&D as a percentage of sales, aiming to increase it from 8% to 9-10% without sacrificing EPS [11][12] - The management anticipates high single-digit EPS improvement starting in 2027, driven by margin expansion and operational improvements [38][56] Business Line Data and Key Metrics Changes - The company is seeing strong growth in the CAS segment, with growth accelerating from about 30% to almost 50% from Q4 to Q1, driven by the Avera capital systems [59][60] - The diabetes business is expected to improve with the launch of two new sensors, which are anticipated to enhance market competitiveness [49][50] Market Data and Key Metrics Changes - The U.S. TAVR business showed slight growth above 6% in Q1, while international markets performed stronger [83] - The company is optimistic about the Ardian product, expecting significant market development following a favorable CMS announcement [77][78] Company Strategy and Development Direction - The management emphasizes the need to capitalize on current growth drivers and accelerate M&A activities to enhance the portfolio [6][19] - The company is committed to maintaining a diverse portfolio while focusing on high-growth areas such as cardiac ablation and hypertension [21][22] Management's Comments on Operating Environment and Future Outlook - Management acknowledges past operational challenges but believes they are now in a better position to pursue M&A and drive growth [19][25] - The company is confident in its growth trajectory, particularly in the second half of the year, with several product launches expected to contribute positively [48][88] Other Important Information - The company is addressing gross margin compression through better pricing strategies and operational improvements, with expectations for consistent gross margin improvement over time [28][36] - The management is focused on the upcoming tibial launch, which is anticipated to be a significant growth driver [86][88] Q&A Session Summary Question: What areas does Elliott want to see improvement in? - Management indicated alignment with Elliott's focus on capitalizing on growth drivers and accelerating M&A activities [5][6] Question: Why has the company done less M&A compared to peers? - The management cited operational issues and a focus on strengthening the company's foundation as reasons for the slower pace of M&A [19][25] Question: What is the outlook for the diabetes business? - The management expressed optimism about the diabetes segment, highlighting the upcoming launch of two new sensors as a key growth factor [49][50] Question: How does the company plan to improve gross margins? - The management outlined strategies including better pricing management, cost control, and innovation to drive gross margin improvement [28][36] Question: What is the expected ramp for the Ardian product? - Management is confident in the Ardian product's market potential and is focused on market development following a favorable CMS decision [77][78]

Financial Data and Key Metrics Changes - The company is experiencing a significant moment with transformational innovation, as noted by management, indicating a potential inflection point in growth [5] - Management aims to improve R&D as a percentage of sales from 8% to 9-10% without sacrificing EPS [10] - The company expects to deliver high single-digit EPS improvement starting in 2027, driven by margin improvements and operational efficiencies [40][60] Business Line Data and Key Metrics Changes - The company is focusing on high-growth areas such as cardiac ablation and AFib, with recent acquisitions like Afera contributing to growth [20][22] - The diabetes segment is expected to improve with the launch of two new sensors, which are anticipated to drive growth in the U.S. market [52][54] - CAS growth accelerated from about 30% to almost 50% from Q4 to Q1, with expectations to add an incremental $1 billion in revenue by early 2027 [63] Market Data and Key Metrics Changes - The U.S. TAVR business showed slight growth of above 6% in Q1, while international markets performed stronger [88] - The company is optimistic about the Ardian product line, anticipating significant market development following a favorable CMS announcement [80] Company Strategy and Development Direction - The management is committed to capitalizing on current growth drivers and accelerating margin improvement through M&A and portfolio optimization [6][20] - The company is not considering a wholesale breakup but is open to trimming down the portfolio if it enhances shareholder value [13][17] - The focus remains on innovation and operational improvements to drive differentiated top-line and bottom-line growth [12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the operational foundation of the company, stating that past supply chain and quality issues are now behind them [20] - The company is optimistic about the back half of the year, expecting growth drivers to contribute positively to performance [50] - Management is closely monitoring the competitive landscape and is committed to evaluating the performance of key investments like the Hugo system [45] Other Important Information - The company is experiencing gross margin pressures due to tariffs and product mix but expects improvements as operational efficiencies are realized [31][34] - The management highlighted the importance of pricing strategies and cost management as key drivers for margin improvement [36][39] Q&A Session Summary Question: What areas does Elliott want to see improvement in? - Management indicated alignment with Elliott's focus on capitalizing on growth drivers and accelerating margin improvement through M&A and portfolio management [5][6] Question: Why has the company done less M&A compared to peers? - Management attributed the lower M&A activity to operational issues during COVID but expressed confidence in pursuing more deals moving forward [20][28] Question: How does the company plan to improve gross margins? - Management outlined strategies including better pricing management, cost controls, and innovation to drive gross margin improvements over time [36][39] Question: What is the outlook for the diabetes business? - The diabetes segment is expected to improve significantly with the launch of new sensors and a new durable pump, enhancing competitive positioning [52][54] Question: How does the company view the TAVR business? - Management remains confident in the TAVR franchise, citing recent product improvements and strong data supporting their market position [89]